Analysts who follow Apellis Pharmaceuticals Inc (APLS) on average expect it to add 81.10% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy.
That average rating earns APLS an Analyst Ranking of 71, which means it ranks higher than 71 of stocks, based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With Apellis Pharmaceuticals Inc Stock Today?
Apellis Pharmaceuticals Inc (APLS) stock is down -2.55% while the S&P 500 has risen 0.67% as of 2:27 PM on Thursday, Sep 24. APLS is lower by -$0.77 from the previous closing price of $30.22 on volume of 780,560 shares. Over the past year the S&P 500 is up 9.17% while APLS has risen 16.40%. APLS lost -$7.61 per share the over the last 12 months.